Bryonia Alba 30C vs 200C: What the Potency Numbers Actually Change

What the C Scale Measures, and Where 30 and 200 Sit

Bryonia alba is a climbing plant of the cucumber family, known in English as white bryony. Its root is the part used in preparation. In the C scale, each step means the starting material is diluted by a factor of one hundred, with vigorous shaking between steps. A 1C preparation is one part plant material to ninety-nine parts diluent; a 2C takes one part of the 1C and dilutes it again by the same factor.

That arithmetic is what separates the two potencies under discussion. A 30C has passed through thirty successive hundredfold dilutions, and a 200C through two hundred. The gap between them is not a small step up a smooth ladder. Each additional dilution multiplies the previous dilution by another hundred, so 200C sits far beyond 30C in a way that is difficult to picture from the numbers alone.

This is the central point for anyone comparing the two: on the C scale, higher numbers mean more dilution, not more of the original substance. In everyday language a "stronger" medicine usually contains more active ingredient. Here the convention runs the other way, and practitioners use the word potency rather than strength to keep the two ideas apart.

How Far Apart 30C and 200C Really Are

The difference in dilution factor between the two potencies is 170 powers of one hundred. Written out, a 30C corresponds to a concentration of one in 10^60, and a 200C to one in 10^400. For scale, common estimates put the number of atoms in the observable universe at roughly 10^80. A 30C is already past the point at which, by simple counting, the original substance is unlikely to be present; a 200C is vastly further past it.

This is why the comparison is not straightforwardly about dose in the pharmacological sense. At neither potency can you reason about the amount of bryony delivered, because the amount is, by any ordinary chemical measure, effectively nil. Whatever distinction practitioners draw between 30C and 200C rests on the preparation process and on clinical convention, not on measurable quantities of plant material.

It is worth being explicit about what follows from that. If you are trying to compare the two by asking which one contains more bryonia, the question does not have a useful answer. The meaningful differences lie in how each potency is used, how often it is repeated, and what practitioners report about the pace and intensity of response.

Why Practitioners Reach for One Rather Than the Other

In the prescribing tradition, potency selection is treated as a judgement about the case rather than a fixed rule. A common line of reasoning holds that lower potencies such as 6C or 30C suit situations where the picture is incomplete, where symptoms are changing quickly, or where the person is being managed over a period and doses may need repeating. Higher potencies such as 200C or 1M are often reserved for cases where the symptom picture is unusually clear and stable.

The practical consequence is a difference in rhythm. A 30C is frequently given on a repeating schedule because its action is thought to be shorter and gentler. A 200C is more often given as a single dose, with the prescriber waiting to observe the response before deciding whether anything further is needed. That difference in repetition matters more to day-to-day experience than the abstract dilution figures do.

Some practitioners also describe the two in terms of depth, arguing that higher potencies act on more general or constitutional patterns while lower potencies address more local or recent complaints. This is a claim within a particular framework of practice. It is not a finding from controlled research, and it should be read as a description of how prescribers think rather than as an established mechanism.

What the Research Literature Does and Does Not Establish

Bryonia alba has been studied in its own right, most visibly in a randomised trial of a 30C preparation given to patients hospitalised with COVID-19, published in 2021. That trial reported differences on some secondary measures. It was a single study in a specific population, and subsequent discussion has raised questions about design and about how far the findings generalise. One trial is not a basis for broad claims about the remedy.

Beyond that, the wider evidence base for ultra-high dilutions is contested. Independent assessments of the field have repeatedly concluded that effects attributed to these preparations are not consistently separable from placebo, while practitioners point to individual responses and to the difficulty of designing trials that match how the remedies are actually prescribed. Both of those positions exist in the literature, and a reader comparing 30C with 200C should know that the comparison itself has not been settled by trial data.

What this means for the specific question: there is no body of research showing that 200C outperforms 30C, or the reverse, for any named condition. The choice between them is made on traditional grounds. Anyone presenting a confident head-to-head verdict is going beyond what has been demonstrated.

Safety Considerations When Potencies Differ So Widely

Because neither potency contains measurable plant material, the direct toxicity risk from the dilution itself is not the main concern. The relevant risks are indirect. The first is delay: if a symptom such as a persistent cough, unexplained pain, or a fever in a child is treated with a remedy while a treatable condition goes unassessed, the harm comes from the waiting, not the sugar pill.

The second concerns high potencies specifically. Some practitioners advise caution with 200C and above in certain situations, including during pregnancy, in infants, and in people taking multiple conventional medicines, on the reasoning that a stronger reaction is possible. Whether or not that reasoning holds, the advice reflects how the potencies are regarded within the tradition: 200C is treated as the more consequential of the two.

Bryonia itself, in its undiluted plant form, is toxic. The root can cause severe gastrointestinal upset if eaten, and cases of poisoning from the fresh plant have been documented. That hazard belongs to the plant, not to the 30C or 200C preparations, and it is one reason the two should never be confused with herbal tinctures or with bryony growing in a garden.

Practical Differences in How Each Potency Is Taken

The two potencies arrive in the same physical forms: sucrose or lactose pills, sometimes granules, occasionally a liquid. The handling instructions are broadly similar, with the remedy tipped into a cap rather than taken from the container by hand, and placed under the tongue to dissolve. Nothing about the appearance of a 30C pill distinguishes it from a 200C pill; the label is the only guide.

Where they diverge is in frequency and in what happens after a dose. A typical 30C schedule might involve a dose two or three times a day for a short period, then stopping. A 200C is more commonly a single dose followed by a wait of days or longer, with the prescriber looking for a change before repeating. Taking 200C on the same frequent schedule as 30C is not standard practice.

If you are choosing between them yourself rather than through a practitioner, that difference in repetition is the most concrete thing to hold on to. It also points to why a practitioner's assessment is worth having: potency and repetition are usually decided together, and getting one without the other is only half the decision.

Reading Potency Claims Critically

Claims about 30C versus 200C often lean on the word strength, which imports assumptions from ordinary medicine that do not transfer. A page that says 200C is "ten times stronger" is applying arithmetic that does not match how the C scale works, where the step from 30C to 200C is not a multiple but an enormous exponential gap. A page that says 200C is "weaker" because it is more dilute is making the opposite error in the other direction.

A more useful way to read such claims is to ask what is being asserted. Statements about preparation and dilution are checkable. Statements about which potency suits which case are traditional guidance, and should be labelled as such. Statements about clinical superiority need trial evidence, and for this comparison that evidence is thin.

For anyone weighing the two, the honest summary is that the difference is real within the tradition and negligible in chemical terms, and that the choice is normally made on the basis of the case picture and the intended dosing rhythm. If a health concern is significant, persistent, or worsening, the appropriate step is to have it assessed by a qualified clinician rather than to adjust potency on your own.